Cyclacel Pharmaceuticals to Announce Q1 2024 Financial Results

May 8, 2024 - Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company focusing on innovative cancer treatments derived from cancer cell biology, is set to release its first quarter 2024 financial results on Tuesday, May 14, 2024. On the same day, the Company will hold a conference call and live webcast at 4:30 p.m. Eastern Daylight Time.

The conference call can be accessed domestically at (888) 632-3384 and internationally at (785) 424-1794. An archive of the call will be available by dialing (800) 938-1584 for domestic access and (402) 220-1542 for international access, using the code CYCCQ124. Additionally, the live and archived webcast can be accessed by visiting Cyclacel's Corporate Presentations page on their website, www.cyclacel.com. The webcast archive will be available for 90 days, while the audio replay will be accessible for seven days.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments that focus on cell cycle, transcriptional regulation, and mitosis biology. The company’s transcriptional regulation program is centered around fadraciclib, a CDK2/9 inhibitor, and its anti-mitotic program includes CYC140, a PLK1 inhibitor. Both programs are currently being tested in patients with solid tumors and hematological malignancies. Cyclacel aims to establish a diversified biopharmaceutical portfolio with a pipeline of unique drug candidates addressing various oncology and hematology indications. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!